US Compression Therapy Market 2026 – 2035

The US compression therapy market size is estimated at USD 1.58 billion in 2025 and is estimated to grow by USD 1.63 billion by 2026 to about USD 1.95 billion by 2035 at a CAGR of 2.10% between 2026 and 2035.

The market is growing due to the increasing cases of chronic venous diseases, the rising cases of diabetes, the rising aging population, the rising cases of obesity, the technological advances of compression devices, the rising level of awareness of the benefits of compression, and the favorable reimbursement policies.

Market Highlight

• The US compression therapy market share is about 36% in the year 2025, which is the largest market in the entire world in one country.

• By product type, the compression garments segment had close to 68% of the market share in 2025.

• By product type, the compression pumps segment has the highest CAGR of 4.8% between 2026 and 2035.

• By technology, the biggest market share of 66% was recorded in the segment of static compression therapy in the year 2025, and dynamic compression therapy is projected to grow at a CAGR of 5.2% over the period of time between the years 2026 and 2035.

• Application of venous leg ulcers will take 39.2% market share in 2025 and lymphedema treatment is increasing at a rate of 3.9% CAGR.

• The compression therapy sector contributed directly to more than 45,000 employment opportunities in the US in 2024 that comprised manufacturing, distribution, clinical services, and technical support.

Significant Growth Factors

The US Compression Therapy Market Trends present significant growth opportunities due to several factors:

• Rising Prevalence of Chronic Venous Disorders and Diabetic Complications:

Chronic venous insufficiency, venous leg ulcers, and associated circulatory disorders are significant health issues in the United States, and compression therapy poses the main non-invasive intervention mode prescribed by vascular experts and wound care specialists in the management of the ever-decapacitating pathologies. The National Institutes of Health claim that chronic venous insufficiency occurs in about 6-7 million Americans, and the prevalence rates are much higher among persons aged 60 and over, which is one of the reasons why the patient population in question demands the use of compression therapy on a long-term basis to be able to prevent the evolution of the disease and enhance the quality of life. Venous leg ulcers that constitute 60-70% of all chronic leg ulcers in the United States afflict 1-2% of the general population with a lifetime prevalence of between 3-5% in persons above the age of 65 years, generating a long-term requirement for compression bandages, stockings, and wraps, which are vital in the healing and prevention of ulcer recurrence.

The possibilities of venous leg ulcer recurrence are quite high, about 67% in the case of ineffective compression therapy, which is why it is necessary to pay a lot of attention to the correct use of compression in order to guarantee the positive final results of the affected patient. According to the American Diabetes Association, there were 38.4 million Americans with diabetes (11.6% of the US population) in 2024, and about 90-95% of diabetes cases were type 2 diabetes that is strongly related to obesity, inactive lifestyles, and aging populations, whereby diabetic patients were at high risk of peripheral vascular disease, neuropathy, and foot ulcers requiring compression therapy interventions. Obesity epidemic is a substantial contributor to the prevalence of venous disorder, and 24.2% of obese adults now have diabetes versus 6.8% of nonobese individuals, as noted in 2024 CDC data, which is a compounding risk factor for venous insufficiency, lymphedema, and leg ulcers, which compression therapy is effective in managing. In the United States, diabetes-related complications lead to about 154,000 lower-extremity amputations every year, and African Americans are four times more likely than whites to suffer amputation due to diabetes-related vascular complications, demonstrating issues in access to healthcare and the critical need for easily available compression therapy intervention to prevent lower-limb endangering vascular problems.

The pressure of the aging American population increases the compression therapy demands, as the population aged 65 and above is predicted to grow to 73 million in 2030, which constitutes 21% of the overall population, and among the elderly in this category, the discrimination of venous disorders, mobility issues, and chronic illnesses requiring the aid of long-term compression therapy is significantly higher.

• Technological Advancements in Smart and Dynamic Compression Systems:

The compression therapy market is undergoing a technological revival with the launch of smart, connected compression devices that possess digital sensors, automatic pressure management, and mobile connectivity that allows real-time monitoring, personalized pressure treatment, and enhanced compliance of patients with the use of easily accessible interfaces and remote supervision by healthcare providers.

The introduction of the Kendall SCD SmartFlow Compression System in November 2024 by Cardinal Health is an important evolution in the technology of pneumatic compression by providing tailored intermittent compression therapy (preventing venous thromboembolism or VTE) in hospital patients and high-risk individuals by customizing pressure modulation and adding additional comfort functionality to increase patient compliance. In 2024, tactile medical launched the Flexitouch Plus system, an innovative pneumatic compression therapy to manage lymphedema with better garment design, controlling capabilities, and programs customizable by patients to provide healthcare-grade quality home care therapy and increased patient agency. Modern compression devices have the capability to be remotely monitored by their healthcare providers through the integration of Bluetooth and Wi-Fi connections, and the machinery can relay data on treatment compliance, pressure settings, and usage patterns to allow monitoring of adherence and optimization of therapeutic choices to maximise treatment outcomes in the management of chronic conditions. Intelligent compression stockings with built-in pressure sensors and activity monitors are taking shape, prototypes of major manufacturers are measuring the amount of compression applied at each time of the day, reminding patients of insufficient compression, and showing mobility data in support of comprehensive holistic vascular health care.

The advances in fabric technology such as breathable, moisture-wicking fabrics, antimicrobial treatments, and seamless knitting are leading to enhanced comfort and wearability in compression garments, as well as overcoming the problem of patient compliance that has traditionally limited the effectiveness of compression therapy with 49.4% of patients surveyed in clinical literature reporting that feeling as a barrier to continued use. Three-dimensional knitting technology is capable of graduated compression designed with anatomical contours giving the best pressure distribution through the limb segments with compression gradients precisely engineered to give maximum pressure at the ankle which gradually diminishes towards the thigh to simulate physiological venous return improvement. Hybrid compression systems that use a combination of non-pneumatic compression garments and intermittent pneumatic compression are being increasingly used as a treatment in the management of complex lymphedema, and integrated strategies provide better fluid mobilization and long-term edema control than either system alone is especially useful with patients with advanced or recalcitrant lymphedema. Adjustable compression wraps that can be self-applied by patients and have adjustable pressure through the use of Velcro closures and modular design can be used to enhance usability by elderly patients and individuals with lesser dexterity than traditional elastic stockings, which need help in donning and doffing.

What are the Major Advances Changing the US Compression Therapy Market Today?

• Smart Compression Devices with Digital Integration:

The advent of digitally enabled compression therapy devices is a paradigm shift from passive mechanical compression to active, intelligent systems that can measure, control, and record treatment in real-time and have a profound positive effect on treatment precision, tracking of patient compliance and measurement of clinical outcomes vital in delivering evidence-based care. Modern pneumatic compression machines are now fitted with pressure sensors that constantly check the level of compression applied, automatically adjust to changes in the circumference of the limb during treatment sessions and alert users to improperly applied compressions to achieve consistent therapy delivery to counter the problem of varying pressure adjustments of previous manual pressure adjustments. Smart compression systems use mobile applications to allow patients to track their treatment sessions, log adherence data, access educational information, get drug reminders, and communicate with their healthcare providers via secure messaging platforms that form complete digital health ecosystems that enable the management of chronic diseases beyond compression therapy itself. Evidence-based treatment protocols, recommendations on the pressure setting depending on the diagnosis and the characteristics of patients, and outcome predictive algorithms integrated into the compression therapy systems are clinical decision support tools that can assist clinicians to optimize therapeutic interventions and standardize care delivery across various practice environments.

The remote patient monitoring facilities would allow medical practitioners to access compression device use data, detect non-adherent patients who need intervention, and modify treatment parameters without face-to-face interactions, enhancing care delivery and efficiency and preserving clinical oversight needed to handle complex and long-term conditions such as lymphedema and chronic venous insufficiency. Machine learning algorithms and artificial intelligence are undergoing development to examine usage patterns of compression therapy, predict the outcome of the treatment according to the characteristics and adherence behaviors of patients and give them personalized advice that maximizes their treatment as well as to identify patients who are at risk of not complying or developing the disease that may require increased treatment. Combination of wearable activity monitors and compression devices allows comprehensive health monitoring, where physical activity level, sleep habits, and mobility behaviors are represented in holistic data supporting the idea of lifestyle change to supplement compression therapy in managing venous and lymphatic disorders.

• Advanced Materials and Comfort-Focused Design Innovation:

Innovations in the field of materials science are transforming the existing production of compression garments, with a new generation of materials that promises more durability, breathability, better moisture management, and antimicrobial properties that could help in addressing the problem of patient discomfort, which previously limited the utilization of compression therapy despite its proven clinical efficacy. Compression fabrics made in microfiber technology using ultra-fine synthetic fibers produce the ultimate package in compression fabrics that have the softness of silk and are highly moisture wicking, which has a significant effect on the wearing comfort of all-day wear garments, such as compression stockings, without the loss of their therapeutic compression attributes over the extended periods of wear necessary to comply with the all-day use criteria. Antimicrobials applied to compression garments inhibit the growth of bacteria, reduce the formation of odor, and minimize the risks of skin irritation, especially in cases where patients have compression garments over a prolonged duration or have compromised skin integrity that predisposes them to infection such as venous ulcers or lymphedema.

Seamless knitting platforms are able to remove pressure points and decrease the risk of skin chafing and enhance the aesthetic of compression garments with 3D knitted products which have an anatomically designed shape that fits the shape of various limbs, which is more comfortable and therapeutic than traditional sewed-seam construction. Beading (silicone) on the stocking tops does not promote movement of the garment as much as other methods, which involve high pressure and adhesives, and eliminates patient complaints about compression stockings rolling down the thighs and having to constantly adjust the garment level throughout the day, which is especially problematic with higher compression levels. Breathable compression garments using advanced fiber structures can facilitate better airflow and dissipation, leading to resolutions of complaints of sweating and overheating, which is especially pertinent in the context of using compression garments of patients in hot climates or patients who wear breathable compression garments all year round to manage chronic cases.

The variety of colors and patterns in compression stockings has grown exponentially, with color variety and pattern variety being provided by the manufacturers and fashionable designs, as well as a variety of colors and patterns that help to reduce the medical device stigma (especially in the case of younger patients, who may find it hard to associate compression products with everyday clothes).

• Evidence-Based Clinical Practice Guidelines and Quality Metrics:

Evidence-based clinical practice guidelines are under development to compress therapy use, which is leading to the standardization of care, better suitability of the treatment, a better patient outcome, and the average of clinical effectiveness across various venous and lymphatic conditions, which justifies reimbursement. In 2024, the American Venous Forum and Society of Vascular Surgery issued updated guidelines with specific recommendations on the indications of compression therapy, contraindications, levels of compression, choice of product used and duration of treatment in the management of different venous conditions, which has set clinical standards of proper compression therapy use. In wound care facilities and vascular centers, compression therapy outcomes such as ulcer healing rates, edema reduction, pain scores and quality of life improvement outcomes are systematically monitored, and registries of actual care outcomes support the use of evidence-based practice and offer care optimization opportunities.

Certification programs in compression therapy are also growing in numbers to include clinicians, such as nurses, physical therapists, and lymphedema professionals, with standardized training being the most important means of competency in assessment, product choice, fitting methods, and education of patients that is necessary to deliver compression therapy safely and effectively, with special attention given to complex cases. The pattern in wound care centers in the United States is the use of standardised compression therapy guidelines, depending on wound specifics, the measurements of the limb, and patient variables, decreasing the scope of variation in treatment and enhancing results when compared with non-standardised methods of wound care delivery with no evidence-based background. Models of value-based care in which compression therapy cost-efficiency measures, patient-reported outcomes, and measures of complication avoidance have been incorporated are beginning to be implemented, with reimbursement being tied to the value of therapy instead of merely providing products so as to facilitate their use and make adherence support interventions that enhance long-term outcomes.

• Reimbursement Expansion and Patient Access Improvement:

Undeniably, the advancement of compression therapy products and services has led to reimbursement expansion and patient access improvement, as insurance coverage encompasses therapeutic value, covers more indications, and raises the level of reimbursement to allow patients to access the right compression therapy interventions previously restricted by high out-of-pocket cost barriers. The 2024 expansion of Medicare coverage of pneumatic compression devices to be used in the home applies to the treatment of lymphedema and chronic venous insufficiency with documented medical necessity by no longer limiting the coverage to the institutional setting, which will provide millions of beneficiaries who need long-term compression therapy with the opportunity to obtain coverage.

The commercial insurance prior authorization procedures required of compression therapy have been simplified in most health programs, and the documentation requirements have also been simplified and the authorization duration has been extended and the non-physician prescribers such as nurse practitioners and physician assistants, have been recognized to enhance access and ease the administrative burden on healthcare providers. Largely in response to long-standing disparities in compression therapy access between underserved populations, Medicaid programs in many states have increased compression therapy coverage of graduated compression stockings to prevent venous insufficiency, compression pneumatic devices to prevent lymphedema, and special wrapping systems to treat venous ulcers, among other treatments. Suppliers of durable medical equipment are raising the number of compression therapy products at their disposal, have larger stocks of their products, and are providing same-day installations and patient education that aids in the selection and use of compression products, and the distribution network is improving in terms of making compression products available to patients when needed. Compression products are offered to uninsured and underinsured patients at no cost or at a reduced cost through patient assistance programs and manufacturer-sponsored programs, where eligibility is determined by their financial need and where medical necessity is determined as addressing affordability barriers that disproportionately impact vulnerable populations at the highest risk of venous and lymphatic disorders.

Category Wise Insights

By Product Type

Why Compression Garments Lead the Market?

In 2025, compression garments take the biggest share of about 68% of the total market share. This predominance indicates that compression garments have multiple purposes in therapeutic and preventive interventions, they are simple to use in both hospital and home environments, they are highly recommended by physicians in managing chronic venous disease and patients prefer the garment therapy to highly invasive or intensive interventions. The compression garments prevail because of their capacity to be used long-term and daily in managing chronic disorders, such as venous insufficiency, in preventing deep vein thrombosis during travel and hospitalization, and in sports medicine as a performance-enhancing and recovery-stimulating tool, making them have varied market uses beyond the traditional medical implications.

The biggest sub-segment is compression stockings which occupy about 72% of the compression garments sales with over-the-counter compression mild (15-20 mmHg) of up to 50 mmHg of high compression being used to prevent and manage severe venous disorders and lymphedema that requires clinical care. The wide selection of compression stockings in the forms of knee-high, thigh-high, and pantyhose makes patients able to wear compression stockings according to their therapeutic requirements, fashion, and lifestyle, with knee-high compression stockings taking around 60% of sales because they are easy to apply and cover most of the venous diseases of the lower extremities.

Market data shows that compression garments are a multibillion dollar market in the US alone with an annual growth due to aging population demographics, rising rates of diabetes that cause peripheral vascular complications, and an expanding sports medicine usage of compression garments as an efficient means to provide athletes with benefits in performance. Therapeutic design Graduated compression stockings with maximal pressure at the ankle and decreasing pressure levels all the way to the thigh or knee indicate typical therapeutic design where pressure gradient is the most significant factor in people with venous insufficiency or those with a risk of stasis and thrombosis with prolonged immobility. The market of medical-grade compression garments enjoys the benefits of physician prescription of higher compression levels that guarantees proper patient selection, fitting by certified fitter, and insurance reimbursement covers reduced out-of-pocket expenses of patients needing higher compression levels than an over-the-counter product can provide.

The compression pumps are recording the highest growth at a projected CAGR of 4.8% between 2026 and 2035 due to the emerging technologies that have led to stronger compression pumps, stronger indications of lymphedema management and the treatment of venous ulcers, and the increased use of compression pumps in the home care environment to allow the use of treatment long-term, hence compliance to therapy. The Flexitouch Plus system by Tactile Medical and the Kendall SCD SmartFlow by Cardinal Health are next generation pneumatic compression systems that are more comfortable and easy to operate and have a clinical grade practice in the home environment with FDA clearance and insurance coverage, enabling the target population with intensive compression therapy to have them available.

This is due to the fact that the lymphedema market is the biggest contributor to the uptake of the pneumatic compression pump, and about 10 million Americans have either primary or secondary lymphedema, which needs multi-modal care using compression garments, manual lymphatic drainage, and the use of pneumatic compression pumps as the best tools in the management of edema and quality of life. Complex pneumatic compression systems with adjustable pressure levels and repetitive inflation cycles offer better lymphatic fluid mobilization than simple compression because it has been shown to be better used in complex or refractory lymphedema cases that cannot receive sufficient management through the use of garments.

By Technology

Why Static Compression Therapy Dominates the Market?

The biggest segment is that of static compression therapy which will have a share of around 66% in the total market share in 2025. This leadership indicates the clinical efficacy of the use of static compression over most indications, ease of operation such that only a small amount of training may be necessary, cost-effectiveness that compares to dynamic compression systems, and the ability to wear the compression devices all day long to provide therapeutic benefit during the entire waking period. The static compression therapy section includes all forms of compression done in the form of garments and bandages that take care of the continuous and non-varying pressure on the affected limbs, and the therapeutic effects of the compression include a reduction of venous pressure and their ability to prevent edema as well as to enhance venous return that has proven to be effective over decades of clinical study and clinical practice in the diverse patient population. Graded compression stockings are the first-line treatment of chronic venous insufficiency, varicose veins, mild-to-moderate lymphedema and post-thrombotic syndrome and major institutions such as the American Venous Forum and the Society of Vascular Surgery recommend the use of go-round compression stockings as the primary approach to treatment of these diseases affecting millions of Americans each year.

The segment enjoys the virtue of wide product offerings, such as over-the-counter compression stockings at retail pharmacies and online retailers, prescription medical grade compression garments by specialty suppliers, and professional grade compression bandaging systems in wound care and lymphedema management clinics around the country. Compression bandages such as short-stretch, long-stretch, and multi layers bands occupy about 38% of compression product sales, and the products are mainly applied in clinical practice as treatment of venous ulcers, management of acute lymphedema, and postoperative edema management that involves intensive use of short-term compression prior to the changeover to the garment-based maintenance therapy. Clinical effectiveness data shows that correctly used static compression therapy results in 97% healing of venous leg ulcers in patients with good compliance with treatment measures with a range of 16.66-58.62% healing rate within two months based on the type of compression therapy used and compliance monitoring with adherence support as an important issue.

Dynamic compression therapy continues to have the highest growth rate with the expected CAGR of 5.2% between the years 2026 and 2035 due to the technological advancement in pneumatic pumps, increasing evidence on its superior use in complex lymphedema and chronic wounds, widening reimbursement coverage, and more extensive adoption of home care due to its user friendly device designs. Dynamic compression devices are intermittent pneumatic compression that provides cyclical inflation and deflation that simulates muscular contraction and relaxation to improve the lymphatic drainage and venous return better than just using a static compression especially in patients with poor muscle pump functioning or severe lymphatic dysfunction.

Sequential compression devices (SCDs) that are highly prevalent in hospitals as part of the dynamic compression segment to prevent deep vein thrombosis in post-surgical and immobilized patients include SCDs that have been widely used in the market with nearly all US hospitals having stocks of SCDs to accomplish routine VTE prophylaxis and represent a significant market supporting annual replacement and consumable sales. Home-based pneumatic compression systems used to treat lymphedema are the most rapidly expanding sub-segment, and more sophisticated systems such as the Flexitouch and Lymphapress Optimal systems by Tactile Medical provide clinical grade therapy at home and reduce the number of clinic visits and the healthcare expenditures. The extension of the Medicare coverage of home pneumatic compression devices in 2024 accelerated market growth with lymphedema and chronic venous insufficiency getting the green light to allow an estimated 2 million more beneficiaries to receive covered therapy that had previously been restricted by coverage policies or lack of awareness among prescribers and patients.

By Application

Why Venous Leg Ulcers Dominate Compression Therapy Applications?

Venous leg ulcers are the biggest application segment, which will contribute about 39.2% of the total market share in 2025. This leadership portrays the position of venous ulcers as the largest category of chronic leg wounds in the United States, 60-70% of all leg ulcers and the proven ability of compression therapy as the primary evidence-based treatment needed to heal ulcers and prevent recurrence. The American College of Wound Healing and Tissue Repair estimates that 1-2% of the US population will get a wound leg ulcer in their lifetime, and that prevalence increases to 3-5% of the population over the age of 65, which is a large patient population that needs compression treatment as their baseline treatment, notwithstanding other wound healing interventions used.

The causes of venous leg ulcers include the chronic venous hypertension leading to the destruction of the skin and subcutaneous tissues and the protracted high venous pressure causing the leakage of capillaries and inflammation and tissue destruction, resulting in painful and slow healing wounds severely affecting the mobility and quality of life of the patient and incurring significant healthcare expenses due to the long treatment. The compression therapy of venous ulcers generally utilizes multi-layered bandage systems that deliver 30-40 mmHg of compression at the ankle in the early intensive periods of treatment, followed by maintaining compression to reduce venous hypertension, enhance microcirculatory flow and provide an optimal healing environment, which allows the ulcer to be closed in approximately 50-60% of patients within 12 months in combination with proper wound care.

One of the main factors that have led to the adoption of compression stocking therapy as a vital procedure in the treatment of venous ulcers is the fact that recurrence of the ulcers is high (67%); without proper compression therapy, so the maintenance of compression garments is highly important in the prevention of recurrence of the ulcers as well as the management of underlying chronic venous insufficiency that predisposes the development of the ulcers. The venous ulcer care market creates a high compression therapy demand both in the acute management that entails the intensive use of compression bandaging and in the long-term management that necessitates the replacement of compression garments regularly between 3 and 6 months as the elastic properties undergo daily washing and wear. In the United States alone, the economic cost of venous ulcers is over $3 billion per annum in direct healthcare costs and indirect costs of lost productivity, compression-based therapy is a cost-effective intervention, which saves time to heal, and complications and use of healthcare resources are less than with improper compression therapy.

The treatment of lymphedema is reporting the highest growth with a projected CAGR of 3.9% between 2026-2035 due to the rising cancer survival rates and consequent development of secondary lymphedema by cancer treatment, the growing awareness of both healthcare professionals and patients, the increased capabilities of diagnostic tests, and the growing number of treatment options, such as the introduction of pneumatic compression machines. Approximately 10 million Americans have lymphedema and about 20-30% of people who successfully survive cancer develop secondary lymphedema after surgery to remove the axillary lymphedema or as a result of radiation therapy, which is a significant and increasing number of patients so large that their survivorship is longer and they face the risk of lymphedema that requires lifelong management.

Treatment of lymphedema should be via multi-modal therapy comprising compression garments, manual lymphedema drainage, pneumatic compression devices and patient education in complete decongestive therapy measures with compression playing a pivotal role in ensuring the edema is kept down and the disease is not progressed. The market covered by lymphedema compression therapy includes preventive compression sleeves which are used during and after cancer therapy as a measure to lessen the risk of secondary lymphedema, compression garments which are used to manage ongoing edema in the case of established lymphedema, and pneumatic compression devices which are used to provide intensive home-based therapy to deal with complex or refractory cases that are insufficiently controlled with compression garments. Pneumatic compression devices are being more heavily prescribed in the management of lymphedema whereby the evidence indicates that they are more effective than compression garments on their own, especially in managing more moderate to severe lymphedema and the increase in Medicare reimbursement has led to more patients accessing these expensive devices despite clinical necessity.

By End User

Why Hospitals and Clinics Lead End-User Adoption?

The biggest end-user market share, which is about 44% of the market will be in hospitals and clinics in 2025. This preeminence is indicative of the role of the hospitals as a primary site of compression therapy initiation, where sequential compression devices are used most, wound care and lymphedema clinics that offer compression therapy fabrication and management and acute care needs that necessitate the use of compression bandaging to treat venous ulcers and post-surgery edema. Compression therapy in hospitals is mostly comprised of sequential compression devices (SCDs) routinely used to prevent VTE in postoperative patients, in medical patients with compromised mobility and in critically ill patients at high risk of thrombosis, and practically all US hospitals have large inventories of SCDs that can be used to support thousands of patients' daily applications across the country.

The 16.8 million emergency room visits each year in the United States estimated to be associated with diabetes have significant proportions of patients with diabetic foot ulcers, venous leg ulcers, and lymphedema complications that need to initiate or optimize compression therapy, which testifies to the critical role of the hospitals in the acute intervention of compression therapy. Wound care facilities are the main referral centers for complex venous ulcers, lymphedema and chronic wounds that require specialized knowledge in compression therapy, where certified wound care nurses and lymphedema therapists play vital roles in assessment, product selection, fitting and education of patients to have successful results. Innovation in compression therapy occurs through academic medical centers and vascular surgery clinics through clinical research, product testing, and treatment protocol development with the results being published in professional organizations and clinical practice guidelines that overarch the recommended compression therapy as the standard of care in our country. The availability of compression products in hospital formularies affects the prescribing habits and the market share of the competing manufacturers, where the contracts of the group purchasing organization and value analysis committees evaluated compression therapy products in terms of clinical efficacy, cost and ease of use considerations of quality and cost respectively.

The type of healthcare that is growing at the quickest rate is home healthcare, with an estimated CAGR of 5.5% between the years 2026 and 2035 on the basis of the transformation of healthcare delivery to the home whereby complex compression machines are being utilized safely by patients within their homes and home compression therapy is being reimbursed, more so due to the patient preferences which are now to receive care at their homes as opposed to receiving care at a clinical facility. Home healthcare segment includes patients who self-treat chronic conditions with compression garments and home health agencies that offer compression therapy services such as evaluation and bandage and home based pneumatic compression device therapy for lymphedema and venous ulcers that had been facilitated by the ease of use of device designs and remote monitoring.

The Medicare home health benefit covers compression therapy services such as nursing visits to compress bandaging, patient and caregiver education, and adherence monitoring in support of vulnerable elderly patients with management of venous ulcers and lymphedema at home, with an estimated 3.4 million Medicare beneficiaries receiving care in home health services per annum comprising a substantial compression therapy market.

The direct-to-consumer sale of compression therapy via online retailers and manufacturer websites is growing exponentially with patients buying over-the-counter compression stockings to prevent moderate venous insufficiency and prevent edema during travel or athletic recovery without physician prescription or clinical fitting, thus democratizing the access to compression stockings yet raising concern about the proper selection of products and level of compression. The use of telemedicine consultations to manage compression therapy has surged significantly after the COVID-19 pandemic, with remote surgery, digital measuring devices, and patient-reported outcomes facilitating the prescription of compression therapy, adjustment, and monitoring in place of traditional and clinic-based care for these patients due to their transportation difficulties.

Report Scope

List of the prominent players in the US Compression Therapy Market:

• Cardinal Health Inc.

• 3M Company

• SIGVARIS GROUP

• Essity AB

• Julius Zorn Inc.

• HARTMANN USA Inc.

• Bauerfeind USA Inc.

• medi USA

• BIOCOMPRESSION SYSTEMS

• Gottfried Medical Inc.

• Tactile Medical

• Smith & Nephew

• Others

Key Developments

The US compression therapy market has witnessed notable advancements as manufacturers focus on innovation, product expansion, and improved patient compliance.

• In March 2025: Essity added to its JOBST compression therapy the next-generation gradient compression stockings in the US, meant to offer greater comfort and improved moisture to patients with chronic venous insufficiency and lymphedema.

• In December 2024: 3M Health Care illuminated its compression bandaging market with an enhanced multilayer compression system that is more suitable for the treatment of venous leg ulcers to enhance better healing results and cut down on the application time by the clinician in the outpatient and home care facilities.

• In September 2025: AIROS Medical declared a wider implantation in the US of its pneumatic compression gadgets at home (lymphedema management) with rising reimbursement covers and rising implementation of remote patient care systems.

These strategic initiatives have enabled companies to enhance treatment efficacy, expand product offerings across chronic venous disorders and lymphedema, and capitalize on the rising demand for non-invasive therapeutic solutions within the US healthcare system.

The US Compression Therapy Market is segmented as follows:

By Product Type

• Compression Garments

o   Compression Stockings

o   Compression Sleeves

o   Compression Wraps

o   Others

• Compression Bandages

o   Short-Stretch Bandages

o   Long-Stretch Bandages

o   Multi-Layer Bandage Systems

o   Cohesive Bandages

• Compression Pumps

o   Pneumatic Compression Devices

o   Sequential Compression Devices

o   Others

• Other Products

o   Compression Tapes

o   Compression Accessories

By Technology

• Static Compression Therapy

• Dynamic Compression Therapy

• Others

By Application

• Venous Leg Ulcers

• Lymphedema

• Deep Vein Thrombosis

• Varicose Veins

• Post-Surgical Edema

• Sports Injuries

• Other Applications

By End User

• Hospitals and Clinics

• Home Healthcare

• Nursing Care Centers

• Sports and Fitness Centers

• Other End Users

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Specialty Stores